medigraphic.com

2023, Number 3

<< Back Next >>

Rev Hematol Mex 2023; 24 (3)

Approach of COVID-19 induced coagulopathy, from literature to the clinical practice

Samaniego SB, Rodríguez SCA, González CA, Montemayor MJL, Villalón DJ, De la Mora C

Language: English
References: 23
Page: 128-135
PDF size: 233.89 Kb.


ABSTRACT

Objective: To determine the clinical practice of the intentional search of COVID-19 induced coagulopathy at hospital admission and describe its incidence, thrombosis rates and mortality.
Materials and Methods: A retrospective cohort study of adult patients with COVID-19 that required hospitalization was made from April 2020 to May 2021 in a Mexican private hospital. COVID-19 induced coagulopathy diagnosis was established if two of these criteria were met: D-dimer above 1 µg/mL, platelet count below 150 K/µL and international normalized ratio (INR) of 1.2 or higher. The population was divided according to therapy: thromboprophylaxis, anticoagulation vs not-totreat. General characteristics, mortality, length of stay, and thrombosis rates were described for each group.
Results: For a total of 532 patients, 116 were evaluable for COVID-19 induced coagulopathy at hospital admission; the diagnosis was confirmed in 34 of them (29.3%). The thrombosis rates and mortality were 17.6% and 32.3%, respectively. Those who received anticoagulation presented with more severe clinical and biochemical characteristics, hence the length of stay and thrombosis rates were higher in them.
Conclusions: The diagnosis of COVID-19 induced coagulopathy reached 29.3% in the evaluable population. Its search is close to 21.8% of the patients admitted.


REFERENCES

  1. Liao D, Zhou F, Luo L, Xu M, et al. Haematological characteristicsand risk factors in the classification and prognosisevaluation of COVID-19: a retrospective cohort study.Lancet Haematol 2020; 7: 671-78. doi: 10.1016/S2352-3026(20)30217-9.

  2. Huang C, Wang Y, Li X, Ren L, et al. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan,China. Lancet 2020; 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5.

  3. Berlin DA, Gulick RM, Martinez F. Severe COVID-19. N Engl JMed 2020; 383: 2451-2460. doi: 10.1056/NEJMcp2009575.

  4. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.Pathophysiology transmission, diagnosis, and treatmentof coronavirus disease 2019 (COVID-19). JAMA 2020; 324:782-793. doi:10.1001/jama.2020.12839.

  5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parametersare associated with poor prognosis in patients withnovel coronavirus pneumonia. J Thromb Haemost 2020;18: 844-847. doi: 10.1111/jth.14768.

  6. Iba T, Levy J, Levi M, Thachil J. Coagulopathy in COVID-19.J Thromb Haemost 2020; 18: 2103-2109. doi: 10.1111/jth.14975.

  7. Joly B, Siguret V, Veyradier A. Understanding pathophysiologyof hemostasis disorders in critically ill patients withCOVID-19. Intensive Care Med 2020; 46: 1603-1606. doi:10.1007/s00134-020-06088-1.

  8. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LF. The trinity ofCOVID-19: Immunity, inflammation, and intervention. NatRev Immunol 2020;20:363-374

  9. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematologicalfindings and complications of COVID-19. Am JHematology 2020; 95: 834-847. https://doi.org/10.1038/s41577-020-0311-8.

  10. Leentjens J, van Haaps TF, Wessels PF, Schutgens RE,Middeldorp S. COVID-19 associated coagulopathy and antithromboticagents-lessons after 1 year. Lancet Haemotol2021; 8: 524-533. doi: 10.1016/S2352-3026(21)00105-8.

  11. Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo D.Coronavirus disease 2019—associated thrombosis andcoagulopathy: Review of the pathophysiological characteristicsand implications for antithrombotic management.J Am Heart Assoc 2021; 10: e019650. doi: 10.1161/JAHA.120.019650.

  12. Thachil J, Tang N, Gando S, et al. ISTH interim guidanceon recognition and management of coagulopathy inCOVID-19. J Thromb Haemost 2020; 18: 1023-1026. doi:10.1111/jth.14810.

  13. Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, et al.American Society of Hematology living guidelines on theuse of anticoagulation for thromboprophylaxis in patientswith COVID-19. Blood Adv 2021; 5: 3951-395. doi: 10.1182/bloodadvances.2020003763.

  14. Zhang S, Li Y, Liu G, Su B. Intermediate-to-therapeuticversus prophylactic anticoagulation for coagulopathyin hospitalized COVID-19 patients: A systematic reviewand meta-analysis. Thromb J 2021; 19: 1-13. https://doi.org/10.1186/s12959-021-00343-1.

  15. Iba T, Warkentin TE, Thachil J, Levi M, Levy JH. Proposal ofthe definition for COVID-19-associated coagulopathy. J ClinMed 2021; 10: 1-9. doi: 10.3390/jcm10020191.

  16. Connors JM, Levy JH. COVID-19 and its implications forthrombosis and anticoagulation. Blood 2020; 135: 2033-2040. doi: 10.1182/blood.2020006000.

  17. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, et al.Incidence of thrombotic complications in critically ill ICUpatients with COVID-19. Thromb Res 2020; 191: 145-147.doi: 10.1016/j.thromres.2020.04.013.

  18. Al-Samkira H, Karp Leaf RS, Dzik WH, Carlson J, et al. COVIDand anticoagulation: Bleeding and thrombotic manifestationsof SARS-CoV2 infection. Blood 2020; 136: 489-500.doi: 10.1182/blood.2020006520.

  19. Hernández-Garduño. Obesity is the comorbidity morestrongly associated for COVID-19 in Mexico. A casecontrolstudy. Obes Res Clin Pract 2020; 14: 375-379. doi:10.1016/j.orcp.2020.06.001.

  20. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-BracamonteFE. Clinical characteristics and risk factors formortality of patients with COVID-19 in a large data set fromMexico. Ann Epidemiol 2020; 52: 93-98. doi: 10.1016/j.annepidem.2020.08.005.

  21. Zhang S, Li Y, Liu G, Su B. Intermediate-to-therapeuticversus prophylactic anticoagulation for coagulopathy inhospitalized COVID-19 patients: a systemic review andmeta-analysis. Thromb J 2021; 19: 91. doi: 10.1186/s12959-021-00343-1.

  22. Rentsch, CT, Beckman JA, Tomlison L, Gellad W, et al. Earlyinitiation of prophylactic anticoagulation for prevention ofcoronavirus disease 2019 mortality in patients admitted tohospital in the United States: cohort study. BMJ 2021; 372:n311. doi: 10.1136/bmj.n311.

  23. Tiwari NR, Khatib KI, Dixit SB, Rathore P, et al. Anticoagulationin COVID-19: An update. J Crit Care Med 2020; 6:217-233. doi: 10.2478/jccm-2020-0033.




2020     |     www.medigraphic.com